| Death receptors: signaling and modulation A Ashkenazi, VM Dixit science 281 (5381), 1305-1308, 1998 | 8671 | 1998 |
| Safety and antitumor activity of recombinant soluble Apo2 ligand A Ashkenazi, RC Pai, S Fong, S Leung, DA Lawrence, SA Marsters, ... The Journal of clinical investigation 104 (2), 155-162, 1999 | 2866 | 1999 |
| Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family RM Pitti, SA Marsters, S Ruppert, CJ Donahue, A Moore, A Ashkenazi Journal of Biological Chemistry 271 (22), 12687-12690, 1996 | 2501 | 1996 |
| Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors JP Sheridan, SA Marsters, RM Pitti, A Gurney, M Skubatch, D Baldwin, ... Science 277 (5327), 818-821, 1997 | 2275 | 1997 |
| Targeting death and decoy receptors of the tumour-necrosis factor superfamily A Ashkenazi Nature Reviews Cancer 2 (6), 420-430, 2002 | 1924 | 2002 |
| Apoptosis control by death and decoy receptors A Ashkenazi, VM Dixit Current opinion in cell biology 11 (2), 255-260, 1999 | 1777 | 1999 |
| Apo2L/TRAIL-dependent recruitment of endogenous FADD and caspase-8 to death receptors 4 and 5 FC Kischkel, DA Lawrence, A Chuntharapai, P Schow, KJ Kim, ... Immunity 12 (6), 611-620, 2000 | 1296 | 2000 |
| Genomic amplification of a decoy receptor for Fas ligand in lung and colon cancer RM Pitti, SA Marsters, DA Lawrence, M Roy, FC Kischkel, P Dowd, ... Nature 396 (6712), 699-703, 1998 | 1157 | 1998 |
| Apo2L/TRAIL and its death and decoy receptors HN LeBlanc, A Ashkenazi Cell Death & Differentiation 10 (1), 66-75, 2003 | 1154 | 2003 |
| Distinct primary structures, ligand‐binding properties and tissue‐specific expression of four human muscarinic acetylcholine receptors. EG Peralta, A Ashkenazi, JW Winslow, DH Smith, J Ramachandran, ... The EMBO journal 6 (13), 3923-3929, 1987 | 1026 | 1987 |
| Assays and methods using biomarkers A Ashkenazi, K Wagner US Patent App. 11/542,527, 2007 | 980 | 2007 |
| A novel receptor for Apo2L/TRAIL contains a truncated death domain SA Marsters, JP Sheridan, RM Pitti, A Huang, M Skubatch, D Baldwin, ... Current Biology 7 (12), 1003-1006, 1997 | 904 | 1997 |
| Differential hepatocyte toxicity of recombinant Apo2L/TRAIL versions D Lawrence, Z Shahrokh, S Marsters, K Achilles, D Shih, B Mounho, ... Nature medicine 7 (4), 383-385, 2001 | 899 | 2001 |
| From basic apoptosis discoveries to advanced selective BCL-2 family inhibitors A Ashkenazi, WJ Fairbrother, JD Leverson, AJ Souers Nature reviews drug discovery 16 (4), 273-284, 2017 | 853 | 2017 |
| Differential regulation of PI hydrolysis and adenylyl cyclase by muscarinic receptor subtypes EG Peralta, A Ashkenazi, JW Winslow, J Ramachandran, DJ Capon Nature 334 (6181), 434-437, 1988 | 837 | 1988 |
| Apo2L/TRAIL: apoptosis signaling, biology, and potential for cancer therapy A Almasan, A Ashkenazi Cytokine & growth factor reviews 14 (3-4), 337-348, 2003 | 746 | 2003 |
| Death receptor recruitment of endogenous caspase-10 and apoptosis initiation in the absence of caspase-8 FC Kischkel, DA Lawrence, A Tinel, H LeBlanc, A Virmani, P Schow, ... Journal of Biological Chemistry 276 (49), 46639-46646, 2001 | 725 | 2001 |
| Cullin3-based polyubiquitination and p62-dependent aggregation of caspase-8 mediate extrinsic apoptosis signaling Z Jin, Y Li, R Pitti, D Lawrence, VC Pham, JR Lill, A Ashkenazi Cell 137 (4), 721-735, 2009 | 718 | 2009 |
| Death-receptor O-glycosylation controls tumor-cell sensitivity to the proapoptotic ligand Apo2L/TRAIL KW Wagner, EA Punnoose, T Januario, DA Lawrence, RM Pitti, ... Nature medicine 13 (9), 1070-1077, 2007 | 707 | 2007 |
| Death receptor signal transducers: nodes of coordination in immune signaling networks NS Wilson, V Dixit, A Ashkenazi Nature immunology 10 (4), 348-355, 2009 | 693 | 2009 |
